IPO - Atlantic Coastal Acquisition Corp. II

Form Type: S-1/A

Filing Date: 2025-06-06

Corporate Action: Ipo

Type: Update

Accession Number: 000121390025052118

Filing Summary: Abpro Holdings, Inc., a biotechnology company specializing in antibody therapeutics, filed Amendment No. 1 to Form S-1 with the SEC on June 6, 2025, to register 20,699,242 shares of Common Stock for resale. The shares are offered by YA II PN, Ltd., as part of a Standby Equity Purchase Agreement (SEPA), where YA has committed to purchasing up to $50 million worth of Common Stock over time. The registration is not an indication that YA will sell any shares, as they may choose to offer them publicly or privately. The current market situation may lead to a decline in the stock price due to the perception of potential sales by YA. This follow-up is linked to a prior Business Combination of Atlantic Coastal Acquisition Corp. II and Abpro Corporation, completed on November 13, 2024, resulting in the transformation to Abpro Holdings, Inc. The registration highlights the risk factors associated with investing in their stock due to its speculative nature and the company's emerging growth company status, which subject it to reduced reporting requirements for a defined period. The merger included the issuance of approximately 50 million shares to former Abpro Corporation shareholders, with ongoing discussions surrounding stockholder approval for the issuance of additional shares under specific conditions. The document emphasizes the critical nature of warranties and market conditions impacting the pricing and sale of shares in this IPO framework.

Form Type: S-1

Filing Date: 2025-05-22

Corporate Action: Ipo

Type: New

Accession Number: 000121390025046533

Filing Summary: Abpro Holdings, Inc. has filed a registration statement with the SEC for the offer and resale of up to 20,699,242 shares of its common stock. Through a Standby Equity Purchase Agreement with YA II PN, Ltd., the company could raise up to $50 million. Following the merger with Atlantic Coastal Acquisition Corp. II, Abpro Holdings, Inc. is focused on developing antibody therapeutics aimed at severe diseases. As of May 20, 2025, the common stock was priced at $0.25 and warrants at $0.01. This IPO is part of broader efforts to enhance capital and support ongoing development amidst high speculation regarding the viability of raising funds post-merger, which may contribute to share price volatility.

Form Type: CORRESP

Filing Date: 2025-02-10

Corporate Action: Ipo

Type: New

Accession Number: 000121390025011817

Filing Summary: Abpro Holdings, Inc. has submitted a request for acceleration of the effective date for their Registration Statement on Form S-1, registration number 333-284021. The requested effective date is set for 4:30 P.M. New York City time, on February 12, 2025, or as soon as practicable thereafter. This request is made pursuant to Rule 461 under the Securities Act of 1933. The company has provided contact information for Jonathan Talcott from Nelson Mullins Riley & Scarborough LLP for follow-up and notification regarding the acceleration request.

Form Type: S-1/A

Filing Date: 2025-02-07

Corporate Action: Ipo

Type: New

Accession Number: 000121390025011397

Filing Summary: Abpro Holdings, Inc. is filing an amendment to its Form S-1 registration statement for an IPO, offering up to 28,850,000 shares of Common Stock on the exercise of Warrants, alongside a secondary offering of 31,935,312 shares of Common Stock and 13,850,000 Placement Warrants by Selling Securityholders. The company underwent a Business Combination with Abpro Corporation, which was completed on November 13, 2024, leading to the merger and resulting issuance of approximately 50,000,000 shares of Common Stock. This amendment details the terms of the offering, including exercise prices for warrants and the public and private shares issued as part of the transaction. The document notes that the market price of the shares could significantly decline due to the sale of such a large number of shares, and the company requests a regulatory review for compliance under SEC and Nasdaq listing rules.